MedPath
HSA Approval

EPIROZIN OINTMENT 2% W/W

SIN16306P

EPIROZIN OINTMENT 2% W/W

EPIROZIN OINTMENT 2% W/W

August 24, 2021

APEX PHARMA MARKETING PTE. LTD.

APEX PHARMA MARKETING PTE. LTD.

Regulatory Information

APEX PHARMA MARKETING PTE. LTD.

APEX PHARMA MARKETING PTE. LTD.

Therapeutic

Prescription Only

Formulation Information

OINTMENT

**DOSAGE AND ADMINISTRATION** For external use only. Adult and Children: Apply to the affected area 2 to 3 times a day, for up to 10 days depending on the response. The area may be covered with a dressing or occluded if desired. There is no long-term experience of mupirocin in humans. Do not mix with other preparations, as there is a risk of dilution, resulting in a reduction in the antibacterial activity and potential loss of stability of the mupirocin.

TOPICAL

Medical Information

**INDICATIONS** Epirozin Ointment is indicated for the treatment of bacterial skin infections e.g., impetigo, folliculitis and furunculosis.

**CONTRAINDICATIONS** Epirozin Ointment should not be given to patients with a history of hypersensitivity to mupirocin or any of the excipients.

D06AX09

mupirocin

Manufacturer Information

APEX PHARMA MARKETING PTE. LTD.

XEPA-SOUL PATTINSON (MALAYSIA) SDN. BHD.

Active Ingredients

Mupirocin Calcium Eqv Mupirocin

2% w/w

Mupirocin

Documents

Package Inserts

Epirozin Ointment PI.pdf

Approved: August 24, 2021

Download
© Copyright 2025. All Rights Reserved by MedPath